Ignite Creation Date:
2025-12-24 @ 11:57 PM
Ignite Modification Date:
2025-12-25 @ 9:53 PM
Study NCT ID:
NCT04543851
Status:
COMPLETED
Last Update Posted:
2020-09-10
First Post:
2020-08-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
CARA Treatment Pilot Study for Breast Positioning
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-10-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2020-09', 'completionDateStruct': {'date': '2019-11-18', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2020-09-03', 'studyFirstSubmitDate': '2020-08-25', 'studyFirstSubmitQcDate': '2020-09-03', 'lastUpdatePostDateStruct': {'date': '2020-09-10', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-09-10', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-11-04', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants for whom dose volume treatment planning constraints are not met using CARA support for breast setup', 'timeFrame': '12 months', 'description': 'Treatment planning dose constraints are:\n\n\\>=95% of the prescribed dose covering \\>=98% of the breast target tissue, including internal mammary chain when requested by the treating oncologist\n\nvolume of ipsi-lateral lung receiving \\>= 20Gy should be \\<=35%\n\nvolume of heart receiving \\>=25Gy should be \\<=5%\n\nmaximum dose to any point in the body \\<=110% of the prescribed dose\n\nvolume of breast receiving \\>=107% of prescribed dose should be \\<=22 cm\\^3'}, {'measure': 'Number of participants having measured breast skin dose => 110% of the prescribed dose to an area of skin => 1 cm^2', 'timeFrame': '12 months', 'description': 'Skin dose is measured on the breast surface under the carbon fibre device using radio-chromic film. The area of skin receiving 70% of the prescribed dose up to the maximum absorbed dose is measured in 5% dose increments to an accuracy of 0.5 cm\\^2.\n\nIf any participant receives =\\> 110% of the prescribed dose to \\>=1 cm\\^2 area of skin, the study will be stopped.'}, {'measure': 'Number of participants scoring =>6 on the CTCAE Version 4.0 skin assessment', 'timeFrame': '12 months', 'description': 'Participants will undergo a detailed breast skin assessment at baseline, one week prior to RT completion, last week of RT, and one and two weeks post RT using the CTCAE Version 4 skin assessment scoring system as well as examination of the infra-mammary fold for any moist desquamation. The dimensions and location of moist desquamation will be recorded. In the event that a skin reaction of ≥ 6 (indicating ulceration, hemorrhage or necrosis) on the CTCAE V 4.0 scale is reported, the trial will be stopped.'}], 'secondaryOutcomes': [{'measure': 'Workflow measures', 'timeFrame': '12 months', 'description': 'Measured time to accomplish set up and treatment with CARA positioning'}, {'measure': 'Setup reproducability', 'timeFrame': '12 months', 'description': 'Measure required shifts in patient position using kilo-voltage imaging'}, {'measure': 'Doses to organs at risk comparison with standard of care', 'timeFrame': '12 months', 'description': 'Comparison of lung, heart, breast and normal tissue dose versus standard of care'}, {'measure': 'Skin assessment versus skin dose', 'timeFrame': '12 months', 'description': 'CTCAE V4 and specific moist desquamation assessment of breast skin compared with measured skin dose-area data'}, {'measure': 'Patient Reported outcome - skin reaction', 'timeFrame': '12 months', 'description': 'Questionnaire to assess patient reported side effects and skin reaction'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['skin dose', 'skin fold', 'organ at risk'], 'conditions': ['Breast Cancer', 'Side Effect']}, 'referencesModule': {'references': [{'pmid': '40373801', 'type': 'DERIVED', 'citation': 'Malhotra A, Chan EK, Nichol A, Duzenli C. Spatial dose-distribution-based risk mapping to predict moist desquamation in breast radiotherapy. Phys Med Biol. 2025 May 27;70(11). doi: 10.1088/1361-6560/add985.'}, {'pmid': '34303034', 'type': 'DERIVED', 'citation': 'Duzenli C, Koulis T, Menna T, Carpentier E, Arora T, Coope R, Gill B, Lim P, Aquino-Parsons C, Nichol A, Singer J, Ingledew PA, Grahame S, Chan EK. Reduction in Doses to Organs at Risk and Normal Tissue During Breast Radiation Therapy With a Carbon-Fiber Adjustable Reusable Accessory. Pract Radiat Oncol. 2021 Nov-Dec;11(6):470-479. doi: 10.1016/j.prro.2021.06.012. Epub 2021 Jul 21.'}]}, 'descriptionModule': {'briefSummary': 'CARA is a novel Carbon-fibre Adjustable and Re-usable Accessory for supine breast positioning during radiation therapy. CARA was developed at BC Cancer. In this study, twenty patients will be planned and treated with CARA positioning to establish safety and workflow measures of this novel device. The device is designed to remove the infra-mammary skin fold and lateral breast droop which can lead to unwanted dose to normal tissue.', 'detailedDescription': 'This pilot study will investigate the safety and potential benefits of CARA breast positioning by treating 20 patients using the device. Patients will be planned with CARA positioning and standard of care positioning. CARA plans will be evaluated to ensure all treatment planning goals are met and patients will proceed to treatment with CARA positioning. This pilot study will ensure that patients can be safely treated with the CARA and provide us with valuable information from therapists, oncologists and patients about the performance of the current design. This will also inform the direction of design improvements and the production of educational materials for training practitioners in the use of the device. Overall, this will prepare us for a randomized clinical trial of the CARA positioning technique versus current standard of practice to assess whether reduced toxicity can be achieved using the CARA technique.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '19 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nPatients diagnosed with completely excised stage I or II invasive breast cancer, or ductal carcinoma in situ (DCIS), who have undergone breast-conserving surgery and are scheduled to undergo adjuvant breast radiotherapy;\n\nAny breast size with a skin fold of depth 1 cm or greater at the infra-mammary crease at the time of radiation treatment planning, or brassiere cup size equal to or larger than D;\n\nPatients undergoing nodal radiotherapy are eligible if the above criteria are met;\n\nPatients undergoing boost radiotherapy are eligible if the above criteria are met, but only if the surgical scar does not extend inferior to the nipple line of the breast;\n\nLanguage is not a barrier if there are interpreters/family members to translate;\n\nPatients having had chemotherapy are eligible for this study;\n\nExclusion Criteria:\n\nInability to give informed consent or comply with requirements of the trial;\n\nFailure of healing of the surgical scar or significant post-operative wound infection;\n\nPrior radiotherapy to either breast or to the chest;\n\nPresence of significant connective tissue disease (e.g. systemic sclerosis); known radiation hypersensitivity phenotype (e.g. ataxia telangiectasia);\n\nInability to return for assessment at both one week and two weeks following completion of radiotherapy;\n\nBreast reconstruction;\n\nUse of Mepitel® wound dressing product.'}, 'identificationModule': {'nctId': 'NCT04543851', 'briefTitle': 'CARA Treatment Pilot Study for Breast Positioning', 'organization': {'class': 'OTHER', 'fullName': 'British Columbia Cancer Agency'}, 'officialTitle': 'CARA Treatment Pilot Study for Breast Positioning', 'orgStudyIdInfo': {'id': 'H18-02014'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CARA positioning', 'description': 'Planning and Treatment using the CARA Device', 'interventionNames': ['Device: CARA - carbon fibre adjustable re-usable accessory for breast positioning']}], 'interventions': [{'name': 'CARA - carbon fibre adjustable re-usable accessory for breast positioning', 'type': 'DEVICE', 'description': 'Breast positioning to alleviate infra-mammary fold and lateral breast sag', 'armGroupLabels': ['CARA positioning']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'V5T 1K9', 'city': 'Vancouver', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'BC Cancer', 'geoPoint': {'lat': 49.24966, 'lon': -123.11934}}], 'overallOfficials': [{'name': 'Cheryl R Duzenli, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'BC Cancer'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'British Columbia Cancer Agency', 'class': 'OTHER'}, 'collaborators': [{'name': 'Canadian Cancer Society (CCS)', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Medical Physicist', 'investigatorFullName': 'Cheryl Duzenli', 'investigatorAffiliation': 'British Columbia Cancer Agency'}}}}